中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.02 seconds)

    G-Protein-Conjugated Receptor Agonist
    1.
    发明申请
    G-Protein-Conjugated Receptor Agonist 失效
    G蛋白共轭受体激动剂

    公开(公告)号：US20110184031A1

    公开(公告)日：2011-07-28

    申请号：US12597281

    申请日：2008-04-25

    Applicant: Gozoh Tsujimoto ,  Akira Hirasawa ,  Naoki Miyata ,  Takayoshi Suzuki ,  Yoshiyuki Takahara ,  Masaji Ishiguro ,  Yoshie Hata

    Inventor： Gozoh Tsujimoto ,  Akira Hirasawa ,  Naoki Miyata ,  Takayoshi Suzuki ,  Yoshiyuki Takahara ,  Masaji Ishiguro ,  Yoshie Hata

    IPC: A61K31/44 ,  C07D211/72 ,  C07D277/82 ,  C07C63/33 ,  A61K31/428 ,  A61K31/195 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00 ,  A61P1/00 ,  A61P11/00 ,  A61P25/18

    CPC classification number: C07C311/51 ,  C07C217/18 ,  C07D213/74 ,  C07D215/12 ,  C07D257/04

    Abstract: Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or —NR3— [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

    Abstract translation: 公开了一种对GPR-120和/或GPR-40，特别是GPR-120具有激动作用的新的芳烷基羧酸化合物，因此可用作食欲调节剂，抗肥胖剂，糖尿病治疗剂， 胰腺β分化细胞生长增强剂，代谢综合征治疗剂，胃肠道疾病治疗剂，神经病变治疗剂，精神障碍治疗剂，肺病治疗剂，治疗剂 垂体激素分泌障碍或脂质调味剂/调味剂。 芳烷基羧酸化合物由通式（I）表示。 （I）其中环Q表示吡啶基等; R1表示C1-6烷基等; R2表示氢原子，C1-4烷基或C1-4烷氧基; m和n独立地表示1〜5的整数。 X表示氧原子，硫原子或-NR 3 - [其中R 3表示氢原子或C 1-4烷基]。

    THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR DETERMINING PROGNOSIS OF CANCER
    2.
    发明申请
    THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR DETERMINING PROGNOSIS OF CANCER 审中-公开
    癌症治疗剂及确定癌症预防方法

    公开(公告)号：US20140335090A1

    公开(公告)日：2014-11-13

    申请号：US14009026

    申请日：2012-03-30

    Applicant: Soken Tsuchiya ,  Gozoh Tsujimoto ,  Kazuharu Shimizu ,  Yutaka Shimada ,  Kazuhiro Tsukada

    Inventor： Soken Tsuchiya ,  Gozoh Tsujimoto ,  Kazuharu Shimizu ,  Yutaka Shimada ,  Kazuhiro Tsukada

    IPC: C07K16/28 ,  G01N33/574

    CPC classification number: C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  G01N33/57407 ,  G01N33/57446 ,  G01N2333/71 ,  G01N2800/52

    Abstract: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis. The method for detecting cancer comprises measuring FGFRL1 or a fragment thereof extracted from a body tissue, or FGFRL1 or a fragment thereof in blood separated from a living body, and, in this method, a higher concentration of FGFRL1 or the fragment thereof contained therein than the concentration of FGFRL1 or the fragment thereof in the tissue or blood of a healthy individual indicates the presence of cancer.

    Abstract translation: 公开了一种用于癌症的新型治疗剂，例如食管鳞状细胞癌，预测癌症预后的方法，以及使用可以收集的样品来检测或预测癌症如食管鳞状细胞癌的预后的方法 较少侵略 癌症治疗剂包括与FGFRL1进行抗原抗体反应以抑制癌细胞生长的抗体或其抗原结合片段作为有效成分。 用于预测癌症预后的方法包括研究从活体分离的癌组织中FGFRL1的表达水平，并且在该方法中，FGFRL1的高表达水平表示不良预后。 用于检测癌症的方法包括测量从活体分离的血液中从身体组织提取的FGFRL1或其片段或FGFRL1或其片段，并且在该方法中，FGFRL1或其片段含有的浓度高于 健康个体的组织或血液中的FGFRL1或其片段的浓度表示存在癌症。

    Method for diagnosing esophageal cancer
    4.
    发明授权
    Method for diagnosing esophageal cancer 有权
    诊断食管癌的方法

    公开(公告)号：US08945849B2

    公开(公告)日：2015-02-03

    申请号：US12993792

    申请日：2009-05-21

    Applicant: Akira Myomoto ,  Satoko Kozono ,  Hideo Akiyama ,  Hitoshi Nobumasa ,  Yutaka Shimada ,  Gozoh Tsujimoto

    Inventor： Akira Myomoto ,  Satoko Kozono ,  Hideo Akiyama ,  Hitoshi Nobumasa ,  Yutaka Shimada ,  Gozoh Tsujimoto

    IPC: C12Q1/68 ,  G01N33/574

    CPC classification number: C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57446

    Abstract: This invention relates to a composition, kit, or DNA chip for use in diagnosis of esophageal cancer, which comprises a plurality of polynucleotides selected from the group consisting of polynucleotides whose expression levels are varied in esophageal cancer tissues obtained from esophageal cancer patients when compared with cancer-free esophageal tissues obtained from esophageal cancer patients, mutants thereof, and fragments thereof, and to a method for detecting esophageal cancer using the composition, kit, or DNA chip.

    Abstract translation: 本发明涉及用于食管癌诊断的组合物，试剂盒或DNA芯片，其包含多个选自下组的多核苷酸，所述多核苷酸选自食管癌患者食管癌组织中表达水平变化的多核苷酸，与 从食管癌患者获得的无癌食管组织，其突变体及其片段，以及使用该组合物，试剂盒或DNA芯片检测食管癌的方法。

    ESTIMATION OF PROTEIN-COMPOUND INTERACTION AND RATIONAL DESIGN OF COMPOUND LIBRARY BASED ON CHEMICAL GENOMIC INFORMATION
    7.
    发明申请
    ESTIMATION OF PROTEIN-COMPOUND INTERACTION AND RATIONAL DESIGN OF COMPOUND LIBRARY BASED ON CHEMICAL GENOMIC INFORMATION 有权
    基于化学基因信息的蛋白质复合物相互作用和化合物图谱的设计设计

    公开(公告)号：US20100099891A1

    公开(公告)日：2010-04-22

    申请号：US12274744

    申请日：2008-11-20

    Applicant: Yasushi OKUNO ,  Kei TANEISHI ,  Gozoh TSUJIMOTO

    Inventor： Yasushi OKUNO ,  Kei TANEISHI ,  Gozoh TSUJIMOTO

    IPC: C07D209/04 ,  C40B40/00 ,  C40B50/00 ,  C40B30/02 ,  G06F17/10 ,  G06N5/02

    CPC classification number: C40B50/02 ,  G06F19/16 ,  G06F19/24 ,  G06F19/706 ,  G06N99/005

    Abstract: A data processing method for an estimation of compound-protein interaction using both chemical substance information, such as a chemical property of the compound, and biological information, such as sequence information of genes to rationally and efficiently screen compounds. First space representing space coordinates of a first chemical substance group and second space representing space coordinates of a second chemical substance group are defined, and the first chemical substance group is characterized by a first characteristic amount and the second chemical substance group is characterized by a second characteristic amount, and map transformation of the coordinates of the first space and the coordinates of the second space results in the solution so as to increase the correlation between the first space and the second space using a multivariable analysis technique or a machine learning method.

    Abstract translation: 使用化学物质信息（例如化合物的化学性质）和生物信息（例如基因的序列信息）的化合物 - 蛋​​白质相互作用的估计的数据处理方法，以合理且有效地筛选化合物。 定义表示第一化学物质组的空间坐标的第一空间和表示第二化学物质组的空间坐标的第二空间，第一化学物质组的特征在于第一特征量，第二化学物质组的特征在于第二化学物质组 特征量和第一空间的坐标和第二空间的坐标的地图变换得到解，从而使用多变量分析技术或机器学习方法来增加第一空间和第二空间之间的相关性。

    G-protein-conjugated receptor agonist
    10.
    发明授权
    G-protein-conjugated receptor agonist 失效
    G蛋白偶联受体激动剂

    公开(公告)号：US08318781B2

    公开(公告)日：2012-11-27

    申请号：US12597281

    申请日：2008-04-25

    Applicant: Gozoh Tsujimoto ,  Akira Hirasawa ,  Naoki Miyata ,  Takayoshi Suzuki ,  Yoshiyuki Takahara ,  Masaji Ishiguro ,  Mie Hata

    Inventor： Gozoh Tsujimoto ,  Akira Hirasawa ,  Naoki Miyata ,  Takayoshi Suzuki ,  Yoshiyuki Takahara ,  Masaji Ishiguro ,  Mie Hata

    IPC: A01N43/40 ,  A01N43/78 ,  A01N37/12 ,  A01N37/44 ,  A01N43/00 ,  A61K31/445 ,  A61K31/425 ,  A61K31/33 ,  C07D213/72 ,  C07D213/78 ,  C07D277/82 ,  C07C63/00 ,  C07C65/00

    CPC classification number: C07C311/51 ,  C07C217/18 ,  C07D213/74 ,  C07D215/12 ,  C07D257/04

    Abstract: Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or —NR3— [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

    Abstract translation: 公开了一种对GPR-120和/或GPR-40，特别是GPR-120具有激动作用的新的芳烷基羧酸化合物，因此可用作食欲调节剂，抗肥胖剂，糖尿病治疗剂， 胰腺β分化细胞生长增强剂，代谢综合征治疗剂，胃肠道疾病治疗剂，神经病变治疗剂，精神障碍治疗剂，肺病治疗剂，治疗剂 垂体激素分泌障碍或脂质调味剂/调味剂。 芳烷基羧酸化合物由通式（I）表示。 （I）其中环Q表示吡啶基等; R1表示C1-6烷基等; R2表示氢原子，C1-4烷基或C1-4烷氧基; m和n独立地表示1〜5的整数。 X表示氧原子，硫原子或-NR 3 - [其中R 3表示氢原子或C 1-4烷基]。

Patent Agency Ranking